Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Natera (NTRA) and iSpecimen (ISPC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report), Natera (NTRA – Research Report) and iSpecimen (ISPC – Research Report) with bullish sentiments.

Fennec Pharmaceuticals (FENC)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Fennec Pharmaceuticals. The company’s shares closed last Monday at $8.91.

According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of 29.8% and a 70.0% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, Inc., Phathom Pharmaceuticals, and Avadel Pharmaceuticals.

Currently, the analyst consensus on Fennec Pharmaceuticals is a Strong Buy with an average price target of $16.50.

See the top stocks recommended by analysts >>

Natera (NTRA)

In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on Natera. The company’s shares closed last Monday at $45.22.

According to TipRanks.com, Nowak is a 3-star analyst with an average return of 3.4% and a 45.0% success rate. Nowak covers the Healthcare sector, focusing on stocks such as NeuroOne Medical Technologies, Streamline Health Solutions, and InfuSystem Holdings, Inc.

Natera has an analyst consensus of Strong Buy, with a price target consensus of $72.89, representing a 58.8% upside. In a report issued on July 21, Goldman Sachs also maintained a Buy rating on the stock with a $60.00 price target.

iSpecimen (ISPC)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on iSpecimen. The company’s shares closed last Monday at $1.54.

According to TipRanks.com, Hewitt is a 4-star analyst with an average return of 9.8% and a 47.1% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Surgalign Holdings, and Champions Oncology.

iSpecimen has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FENC:

• Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
• Fennec management to meet with Craig-Hallum
• Fennec Announces Results of Annual Meeting
• Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients